MDM2 (fosfo Ser166) Antilichaam

This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues

4193

Q00987

NP_002383.2

Human

MDM2 (phospho-Ser166) antibody was raised against a peptide sequence around phosphorylation site of Serine 166 (A-I-S (p) -E-T) derived from Human MDM2.

Unconjugated

Primary Antibodies

Phospho-Specific

Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Phospho-Specific

Blue Ice

Store antibody at -20˚ C for up to one year.

90 kDa

This antibody detects endogenous level of MDM2 only when phosphorylated at serine 166.

Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200

MDM2

MDM2 oncogene, E3 ubiquitin protein ligase

Homo sapiens

Haupt, Y. et al. (1997) Nature 387, 296-299. Zhou, B. P. et al. (2001) Nat. Cell Biol. 3, 973-981. Grossman, S. R. et al. (1998) Mol. Cell 2, 405-415. Mayo, L. D. and Donner, D. B. (2001) Proc. Natl. Acad. Sci. USA 98, 11598-11603.

HDMX, hdm2, ACTFS, ESA1, M17S1

WB, IHC, IF

89993689

Liquid